Posts

Posted on

ROSEN, A TOP RANKED LAW FIRM, Encourages Velodyne Lidar, Inc. Investors with Large Losses to Secure Counsel Before Important May 3 Deadline – VLDR, VLDRW

PR Newswire

NEW YORK, April 1, 2021 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Velodyne Lidar, Inc. (NASDAQ: VLDR, VLDRW) between November 9, 2020 and February 19, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff deadline.

SO WHAT: If you purchased Velodyne securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Velodyne class action, go to http://www.rosenlegal.com/cases-register-2043.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE:  According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) certain of Velodyne’s directors had failed to operate with respect, honesty, integrity, and candor in their dealings with the Company’s officers and directors; (2) Velodyne was investigating the foregoing matters; and (3) as a result of the foregoing, defendants’ positive statements about Velodyne’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Velodyne class action, go to http://www.rosenlegal.com/cases-register-2043.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

Cision View original content:http://www.prnewswire.com/news-releases/rosen-a-top-ranked-law-firm-encourages-velodyne-lidar-inc-investors-with-large-losses-to-secure-counsel-before-important-may-3-deadline–vldr-vldrw-301261157.html

SOURCE Rosen Law Firm, P.A.

Posted on

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages APA Corporation f/k/a Apache Corporation Investors with Losses to Secure Counsel Before Important April 26 Deadline – APA

PR Newswire

NEW YORK, April 1, 2021 /PRNewswire/ —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of APA Corporation f/k/a Apache Corporation (NASDAQ: APA) between September 7, 2016 and March 13, 2020, inclusive (the “Class Period”) of the importantApril 26, 2021 lead plaintiff deadline.

SO WHAT: If you purchased Apache securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Apache class action, go to http://www.rosenlegal.com/cases-register-2040.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE:  According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Apache intentionally used unrealistic assumptions regarding the amount and composition of available oil and gas in Alpine High; (2) Apache did not have the proper infrastructure in place to safely and/or economically drill and/or transport those resources even if they existed in the amounts purported; (3) these misleading statements and omissions artificially inflated the value of the Company’s operations in the Permian Basin; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Apache class action, go to http://www.rosenlegal.com/cases-register-2040.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-global-investor-counsel-encourages-apa-corporation-fka-apache-corporation-investors-with-losses-to-secure-counsel-before-important-april-26-deadline–apa-301261155.html

SOURCE Rosen Law Firm, P.A.

Posted on

Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine

Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine

U.S. EUA label allows for vaccine vials to remain at room temperature conditions for a longer period (total of 24 hours from previous 12 hours)

Label update also allows for two vial presentations (maximum of 15 doses and maximum of 11 doses)

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that based on submitted stability data, the U.S. Food and Drug Administration (FDA) has authorized the Moderna COVID-19 Vaccine to be kept at room temperature conditions once removed from the refrigerator for administration for 24 hours, an increase from the previous 12 hours. Additionally, a punctured vial is now useable for up to 12 hours, an increase from the previous 6 hours. These new guidelines are reflected in an updated Emergency Use Authorization (EUA) label. The Moderna COVID-19 Vaccine is ready for use and does not need to be diluted.

The FDA also authorized inclusion of a new vial presentation with a maximum of 15 doses of its COVID-19 vaccine. In parallel, the FDA also authorized a maximum of 11 doses of its COVID-19 vaccine in the current format, from the previously authorized 10 doses per vial. The Moderna COVID-19 Vaccine now can be supplied in two vial presentations (a multiple-dose vial containing a maximum of 11 doses or a multiple-dose vial containing a maximum of 15 doses). The Company expects that the 15-dose vials will begin shipping in the coming weeks.

“We are committed to constantly learning and improving to facilitate easier administration of our COVID-19 vaccine for medical staff and accelerate immunization programs. Thank you to the U.S. FDA and CDC for their ongoing collaboration,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We remain focused on doing all that we can to help end the COVID-19 pandemic with a vaccine.”

Moderna is continually learning, adapting and working closely with its partners and the U.S. government to identify ways to facilitate accelerated vaccine administration, address bottlenecks and accelerate production. One identified constraint on the production process has been the capacity of the fill-and-finish process. Moderna studied the possibility of adding more doses to each vial of vaccine to address bottlenecks, accelerate production and reduce the need for consumable materials that are in high demand. Moderna will continue to collaborate with its manufacturing partners and the federal government to increase the efficiency of its production process without compromising quality or safety.

About the Moderna COVID-19 Vaccine

The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the National Institutes of Health (NIH) on February 24, 2020, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of the Moderna COVID-19 Vaccine was dosed on March 16, 2020, 63 days from sequence selection to Phase 1 study dosing. On May 12, 2020, the U.S. FDA granted the Moderna COVID-19 Vaccine Fast Track designation. On May 29, 2020, the first participants in each age cohort were dosed in the Phase 2 study of the vaccine. On July 8, 2020, the Phase 2 study completed enrollment.

Results from the second interim analysis of the NIH-led Phase 1 study of the Moderna COVID-19 Vaccine in the 56-70 and 71+ age groups were published on September 29, 2020 in The New England Journal of Medicine. On November 30, 2020, Moderna announced the primary efficacy analysis of the Phase 3 study of the vaccine conducted on 196 cases. On November 30, 2020, the Company also announced that it filed for Emergency Use Authorization with the U.S. FDA and a Conditional Marketing Authorization (CMA) application with the European Medicines Agency. On December 18, 2020, the U.S. FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older. Moderna has also received authorization for its COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore and Qatar. Additional authorizations are currently under review in other countries and by the World Health Organization.

The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) is supporting the continued research and development of the Company’s COVID-19 vaccine development efforts with federal funding under contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the Company for conducting the program described in the BARDA contract. The U.S. government has agreed to purchase supply of mRNA-1273 under U.S. Department of Defense contract no. W911QY-20-C-0100.

AUTHORIZED USE

Moderna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

IMPORTANT SAFETY INFORMATION

  • Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine.
  • Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID-19 Vaccine. Monitor Moderna COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).
  • Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID-19 Vaccine.
  • The Moderna COVID-19 Vaccine may not protect all vaccine recipients.
  • Adverse reactions reported in a clinical trial following administration of the Moderna COVID-19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site.
  • Severe allergic reactions, including anaphylaxis, have been reported following administration of the Moderna COVID-19 Vaccine during mass vaccination outside of clinical trials.
  • Available data on Moderna COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of Moderna COVID-19 Vaccine on the breastfed infant or on milk production/excretion.
  • There are no data available on the interchangeability of the Moderna COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Moderna COVID-19 Vaccine should receive a second dose of Moderna COVID-19 Vaccine to complete the vaccination series.
  • Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine.
  • Vaccination providers must complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should include the words “Moderna COVID- 19 Vaccine EUA” in the description section of the report.

Click for Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information for more information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company’s development of a vaccine (mRNA-1273) to protect against the SARS-CoV-2 virus, which causes COVID-19; the conditions under which the vaccine can be stored and administered; the number of doses that can be included in each vial; the timing for shipments of vials containing 15 doses; and ongoing improvements to the process for manufacturing and shipping the vaccine. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of the Moderna COVID-19 Vaccine observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; the Moderna COVID-19 Vaccine may prove less effective against variants of the SARS-CoV-2 virus, or the Company may be unsuccessful in developing future versions of its vaccine against these variants; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for the Moderna COVID-19 Vaccine; whether and when any biologics license applications and/or additional emergency use authorization applications may be filed in various jurisdictions and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

Media:

Colleen Hussey

Director, Corporate Communications

617-335-1374

[email protected]

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: FDA Health Infectious Diseases Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Nesco Holdings Completes Acquisition of Custom Truck One Source in Partnership with Platinum Equity and Changes Its Name to Custom Truck One Source, Inc.

PR Newswire

KANSAS CITY, Mo., April 1, 2021 /PRNewswire/ — Nesco Holdings, Inc. (NYSE: NSCO) (“Nesco”), which has been renamed as Custom Truck One Source, Inc. (the “Company”) effective today, in partnership with an affiliate of Platinum Equity, LLC (“Platinum”), today announced the closing of the previously announced transaction to acquire Custom Truck One Source, L.P. (“CTOS”) for a purchase price of $1.475 billion. Nesco and CTOS are leading providers of specialized truck and heavy equipment solutions, including rental, sales and aftermarket parts and service. 

The Company is headquartered in Kansas City, Missouri and led by CTOS co-founder and CEO Fred Ross. The combination creates a leading, one-stop-shop provider of specialty rental equipment, serving highly attractive and growing infrastructure end markets, including the transmission and distribution energy grid, the 5G revolution build-out and critical rail and other national infrastructure initiatives. 

In connection with the Acquisition, the Company has changed its name to Custom Truck One Source, Inc. Its shares of common stock will trade on the NYSE under the ticker symbol “CTOS” beginning on April 5, 2021, and its existing warrants will trade on the NYSE under the ticker symbol “CTOS.WS”. The Company’s leadership team also includes Ryan McMonagle as President and Chief Operating Officer and Brad Meader as Chief Financial Officer, both of whom previously held those positions at CTOS.   

“We are truly excited about bringing these two great companies together,” said Mr. Ross. “We believe that our stockholders will realize the benefits of the combination as we create one of the largest specialty rental fleets in the country. Moreover, we are excited to bring a larger platform to our customers and to continue to provide them with the outstanding customer service they have come to expect from both of us.”

In connection with the Acquisition, Platinum has made an investment and became the majority stockholder of the Company while existing CTOS equity holders, including certain funds managed by the Blackstone Group (“Blackstone”), the majority owner of CTOS prior to the Acquisition, and certain members of the CTOS management team, became minority stockholders of the Company.  Energy Capital Partners (“ECP”) and Capitol Investment (“Capitol”), who together owned approximately 70% of Nesco’s outstanding common stock prior to the Acquisition, retained their entire ownership positions in the Company.

“We look forward to working with the management team to bring these companies together and to putting our playbook in action to create significant shareholder value for many years to come,” said Platinum Equity Partner Louis Samson. “We have a lot of experience in this industry and are excited about the opportunities ahead.”

“We are thrilled to consummate this merger which creates a very unique, valuable, well-capitalized company that is a terrific business and now also will benefit from, and play an important role in, the likely large investment about to be made in our nation’s electrical, telecom and rail infrastructure,” said Mark Ein, Capitol’s CEO and Nesco’s Vice-Chairman who will join the CTOS board. 

FORWARD-LOOKING STATEMENTS

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. When used in press release, the words “anticipates,” “believes,” “will,” “expects,” “look forward” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s management’s control, that could cause actual results or outcomes to differ materially from those discussed in this press release. Important factors, among others, that may affect actual results or outcomes include: the impact of the COVID-19 pandemic on the Company’s business and operations as well as the overall economy; the Company’s ability to integrate the Nesco and CTOS businesses and achieve the expected benefits of the Acquisition in a timely manner; unanticipated costs related to the integration; and general economic and market conditions impacting demand for the Company’s services. For a more complete description of these and other possible risks and uncertainties, please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 9, 2021, as updated by the Company’s subsequent quarterly reports on Form 10-Q.

ABOUT THE COMPANY

The Company is a leading provider of specialized truck and heavy equipment solutions to the utility, telecommunications, rail and infrastructure markets in North America. The Company’s solutions include rentals, sales, aftermarket parts, tools, accessories and service, equipment production, manufacturing, financing solutions, and asset disposal.  With vast equipment breadth, the Company’s team of experts service its customers across an integrated network of locations across North America. For more information, please visit customtruck.com.

INVESTOR CONTACT

Brad Meader, Chief Financial Officer
800.252.0043
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nesco-holdings-completes-acquisition-of-custom-truck-one-source-in-partnership-with-platinum-equity-and-changes-its-name-to-custom-truck-one-source-inc-301261160.html

SOURCE Custom Truck One Source, Inc.

Posted on

ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages fuboTV Inc. Investors with Large Losses to Secure Counsel Before Important April 19 Deadline – FUBO

PR Newswire

NEW YORK, April 1, 2021 /PRNewswire/ — WHY: New York, N.Y., April 1, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of fuboTV Inc. (NYSE: FUBO) between March 23, 2020 and January 4, 2021, inclusive (the “Class Period”), of the important April 19, 2021lead plaintiff deadline.

SO WHAT: If you purchased fuboTV securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the fuboTV class action, go to http://www.rosenlegal.com/cases-register-2038.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 19, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE:  According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) fuboTV’s growth in subscriber and profitability were unsustainable past the seasonal surge in subscription levels; (2) fuboTV’s offering of products was subject to undisclosed cost escalations; (3) fuboTV could not successfully compete and perform as sports book operator and could not capitalize on its only sports wagering opportunity; (4) fuboTV’s data and inventory was not differentiated to allow fuboTV to achieve long-term advertising growth goals and forecasts; (5) fuboTV’s valuation was overstated in light of its total revenue and subscription levels; (6) the acquisition of Balto Sport did not provide the stated synergies, internal expertise, and did not expand fuboTV’s addressable market into online sports wagering; and (7) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the fuboTV class action, go to http://www.rosenlegal.com/cases-register-2038.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

Cision View original content:http://www.prnewswire.com/news-releases/rosen-top-ranked-global-investor-counsel-encourages-fubotv-inc-investors-with-large-losses-to-secure-counsel-before-important-april-19-deadline–fubo-301261138.html

SOURCE Rosen Law Firm, P.A.

Posted on

BLU SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff in a Securities Class Action Lawsuit Against BELLUS Health, Inc.

NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BELLUS Health Inc. (“BELLUS ” or the “Company”) (NASDAQ: BLU) from September 5, 2019, through July 5, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the Southern District of New York alleges violations of the Securities Exchange Act of 1934.

If you purchased BELLUS securities, and/or would like to discuss your legal rights and options please visit Bellus Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors that BLU-5937 had a much higher risk of failing to demonstrate efficacy for chronic cough. Accordingly, despite Merck’s successful Phase 2 study, BLU-5937 had a high risk of failing its Phase 2 study.

Before markets opened on July 6, 2020, Defendants revealed the truth about BLU-5937’s efficacy. They announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked. Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed. The Phase 2 trial showed a “clinically meaningful and highly statistically significant effect only on a subset of patients who had high cough counts (around 32 per day), so the Company was planning a Phase 2b trial focused on those patients.

On this news, indicating that BELLUS had fallen even further behind Merck in developing an FDA-approved treatment for refractory chronic cough, the Company’s stock price plummeted over 75% to close at $2.97 on July 8, 2020 on heavy trading volume.

If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased BELLUS securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/bellushealthinc-blu-shareholder-class-action-lawsuit-stock-fraud-380/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]



Posted on

In letter to British Columbia Premier, Washington Legislators call on province to better regulate mines threatening international rivers, says Conservation Northwest

Letter from Washington State Legislators to B.C. Premier John Horgan highlights transboundary threats from industrial mines and tailings dams, calls for reform

OLYMPIA, Wash., April 01, 2021 (GLOBE NEWSWIRE) — Inadequate oversight of mining operations in southern British Columbia and a lack of financial accountability for clean-up costs is a growing threat to communities and the environment in both B.C. and across the border in Washington state, and needs urgent attention, argues Conservation Northwest, a regional non-profit organization. 

This threat is highlighted in a new

letter sent to B.C. Premier John Horgan from 25 Washington State Legislators

who call for policy reforms to protect transboundary watersheds, fish and wildlife and downstream communities and tribes.

The letter points out that there are at least a dozen operating mines or mining exploration projects in the headwaters of rivers that flow from B.C. into Washington state (click here for a map), and warns that a tailings dam breach at one of these upstream operations – like the one that occurred at the Mount Polley Mine in 2014 causing Canada’s worst-ever environmental disaster – could have major negative environmental and economic impacts on Washington.

“Salmon recovery knows no boundaries. Both the U.S. and Canada have been working to manage and restore salmon runs, but this mining proposal threatens to undo work that has been done,” said state Senator Jesse Salomon, who organized the letter.

“Ecological needs do not recognize political jurisdictions. But political jurisdictions should recognize cross-border ecological needs and the effects of their decisions,” said Sen. Salomon.

Similar arguments were recently made by a hydrogeologist and a member of the Colville Confederated Tribes in this three-minute video, and more than 584 Washingtonians sent approximately 2,080 messages to state lawmakers this session in supporter of the letter.

“We fully support and appreciate the Legislators’ call,” said Mitch Friedman, Executive Director of Conservation Northwest. “British Columbia has tinkered with mining reform for far too long without getting down to the real issues: safety of communities and protection of the environment, both of which are under threat by mines in southwestern B.C. and elsewhere in the province.”

Friedman recently organized a letter from eleven conservation groups and Seattle City Light to Governor Jay Inslee calling on the governor to act through a message to B.C. leadership similar to that from the state lawmakers.

A series of op-eds in The Seattle Times from tribal leaders, fishermen and conservationists have also called attention to mining proposals in the Skagit Headwaters and the lack of sufficient regulations and financial assurances governing mining in the province, and growing threats to U.S. states downstream.

The transboundary region shared by B.C. and the U.S. has become a dangerous hotspot for pollution and chemical spills from the mining industry due to legacy, existing, and proposed mines in the areas upstream of the four bordering states of Washington, Idaho, Montana, and Alaska. Many of these mines are in the headwaters of major rivers that provide critical habitat for salmon and wildlife.

For example, a proposed expansion of the Copper Mountain Mine on the transboundary Similkameen River in southcentral B.C. would increase production by 70 percent and raise the tailings dam to 260 metres, a 73 percent increase and 220 metres higher than Mount Polley’s tailings dam. Maps and more information are availablein this fact sheet.

According to B.C. government inspectors’ reports, Copper Mountain is a repeat offender when it comes to non-compliance with the regulations designed to protect B.C.’s environment.

The Washington State Legislators’ letter dated March 23, 2021 states that both Canada and the U.S. are obliged to honor the 1909 Boundary Waters Treaty, which prohibits pollution on one side of the boundary that would cause injury to life or property on the other side.

But, as the letter points out, that’s only possible if B.C. adopts strict regulations, consistent inspections and financial assurances including full bonding for mines to ensure financial resources are available to clean up when they close or following a disaster like Mount Polley.

A recent audit of B.C.’s stricter mine tailings storage regulations brought in after Mount Polley is expected to show serious shortcomings in how government inspectors ensure mining companies are complying with the revised rules, which raises even more questions about the safety of tailings storage facilities at mine sites throughout the province.

“The safety of communities and the health of the environment in B.C. and Washington state are under serious threat from under-regulated mines and tailings dams, and it’s time for the Horgan government to act,” said Friedman.

ADDITIONAL INFORMATION ON THREATS FROM B.C. MINES TO WASHINGTON RIVERS IS AVAILABLE ON CONSERVATION NORTHWEST’S HEALTHY WATERSHEDS CAMPAIGN WEBPAGE:


www.conservationnw.org/healthy-watersheds-campaign/

  

For More Information:

Mitch Friedman, Executive Director
Conservation Northwest
[email protected]
360-319-9266

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/05c60bc5-6523-4eac-939b-5105aaa92f44



Posted on

Organigram Repays Credit Facilities with Bank of Montreal

Organigram Repays Credit Facilities with Bank of Montreal

In discussions for new revolving facility to maintain financial flexibility

MONCTON, New Brunswick–(BUSINESS WIRE)–
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (collectively, the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that the Company has repaid all outstanding balances (approximately $58.5 million) (the “Repayment”) under the facilities provided under its credit agreement (the “Credit Agreement”) dated November 27, 2020, with Bank of Montreal (“BMO”) as lead arranger and agent as well as a syndicate of other lenders.

The Repayment results in annual interest savings of $2.7 million based on the outstanding balance at the time of Repayment. After giving effect to the Repayment, the Company’s pro forma cash position is $235 million.

The Company is in discussions with BMO to amend the Credit Agreement to provide continuing support and flexibility to Organigram in growing its business on revised terms and conditions.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Indi, SHRED and Trailblazer. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks that could impact the outcome of negotiations and change availability of the Facilities from time to time and the applicable terms thereof including market and credit conditions, general risks related to COVID-19 and risks as disclosed in as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For Investor Relations enquiries:

Amy Schwalm

Vice President, Investor Relations

[email protected]

(416) 704-9057

For Media enquiries:

Marlo Taylor

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Finance Tobacco Banking Specialty Professional Services Alternative Medicine Health Agriculture Retail Natural Resources

MEDIA:

Logo
Logo
Posted on

AMDOCS ALERT: Bragar Eagel & Squire, P.C. is Investigating Amdocs Limited on Behalf of Amdocs Stockholders and Encourages Investors to Contact the Firm

AMDOCS ALERT: Bragar Eagel & Squire, P.C. is Investigating Amdocs Limited on Behalf of Amdocs Stockholders and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amdocs Limited (NASDAQ: DOX) on behalf of Amdocs stockholders. Our investigation concerns whether Amdocs has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On March 31, 2021, Jehoshaphat Research published a short-seller report addressing Amdocs, which alleged, among other things, that: (1) Amdocs overstated its profits, evidenced by steady parent profits despite declining subsidiary profits; (2) there was a concerning pattern of reputable auditors resigning, only to be replaced by “scandal-plagued or tiny shops”; (3) Amdocs “window-dressed” its balance sheets to keep its large borrowing a secret; and (4) all of the foregoing was corroborated by former employees and direct competitors of the Company, including a former American Amdocs executive, who stated that the Company’s “US business was declining at a rate of [around] 7% annually . . . but then we would see the company [publish results that] say North America is stable.”

On this news, Amdocs’ stock price fell sharply on March 31, 2021, to close at $70.15 per share.

If you purchased or otherwise acquired Amdocs shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

[email protected]

www.bespc.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Franklin Wireless Investigating Battery Issues

Company has received reports of battery failure on some devices

SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) — Franklin Wireless Corp. (NASDAQ: FKWL), a market leader in broadband data communications, has been notified of reports of battery issues in some of its wireless hotspot devices. The company is working with its battery and device manufacturing partners and carrier customer to determine the cause and extent of the problem.

About Franklin

Franklin Wireless Corp. (FKWL) is a leader in innovative hardware and software products that support smart tracking and the Internet of Things (IoT), as well as intelligent wireless broadband solutions including mobile hotspots, routers and modems. For more information, please visit www.franklinwireless.com.

Safe Harbor Statement:

Certain statements in this press release constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements, expressed or implied by such forward-looking statements.

Contact: [email protected]